Tiziana Life Sciences plc: Total Voting Rights
Tiziana Life Sciences (NASDAQ: TLSA) has reported issuing 2,043,000 ordinary shares in July 2020 under its ATM sales agreement, raising $4,371,289. The total number of ordinary shares now stands at 168,540,593, with each share providing one vote in company meetings. Tiziana is advancing its clinical programs, including phase 2 studies for Foralumab, a pioneering anti-CD3 monoclonal antibody aimed at treating autoimmune conditions like Crohn's Disease and multiple sclerosis, alongside developing treatments for COVID-19.
- Raised $4,371,289 through issuance of 2,043,000 ordinary shares.
- Initiating phase 2 studies for Foralumab, a novel treatment for Crohn's Disease and multiple sclerosis.
- Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development.
- None.
LONDON and NEW YORK, July 31, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today updated its total voting rights disclosure position.
ATM Issues during July 2020
During the calendar month of July, the Company issued a total of 2,043,000 ordinary shares under the Company’s ATM sales agreement announced on 15 April 2020 to meet sales of a total of 408,600 ADSs under the ATM sales agreement, totaling gross proceeds of
Total Voting Rights
In conformity with DTR 5.6.1, the Company notifies that as at the date of this announcement, it has a single class of shares in issue being Ordinary Shares, the total number of Ordinary Shares in issue will be 168,540,593. There are no Ordinary Shares held in treasury. Each Ordinary Share entitles the holder to a single vote at general meetings of the Company.
The figure of 168,540,593 Ordinary Shares may be used by shareholders (and others with notification obligations) as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
About Tiziana Life Sciences
Tiziana Life Sciences plc is a dual listed (NASDAQ: TLSA & UK AIMS: TILS) biotechnology company that focuses on the discovery and development of novel molecules to treat human diseases in oncology, inflammation and infectious diseases. In addition to milciclib, the Company will be shortly initiating phase 2 studies with orally administered Foralumab for Crohn's Disease and nasally administered Foralumab for progressive multiple sclerosis. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) in clinical development in the world. This phase II compound has potential application in a wide range of autoimmune and inflammatory diseases, such as Crohn's Disease, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For further enquiries:
| Tiziana Life Sciences plc Gabriele Cerrone, Chairman and founder | +44 (0)20 7495 2379 |
| Cairn Financial Advisers LLP (Nominated adviser) Liam Murray / Jo Turner | +44 (0)20 7213 0880 |
| Optiva Securities Limited (Broker) Robert Emmet | +44 (0)20 3981 4173 |
United States:
Investors
Dave Gentry, CEO
RedChip Companies Inc.
407-491-4498
dave@redchip.com
FAQ
What was Tiziana Life Sciences' total fundraising in July 2020?
How many total ordinary shares does Tiziana Life Sciences have as of July 2020?
What is Foralumab and what diseases is it targeting?
What is the primary focus of Tiziana Life Sciences?
